<DOC>
	<DOCNO>NCT01031381</DOCNO>
	<brief_summary>This study investigate efficacy well safety RAD001 combination bevacizumab recurrent ovarian , peritoneal , fallopian tube cancer . RAD001 take orally daily bevacizumab administer every 14 day . The study conduct period 3 4 year .</brief_summary>
	<brief_title>Study RAD001 Bevacizumab Recurrent Ovarian , Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description>In trial , approximately 50 patient receive study drug , RAD001 combination bevacizumab ( Avastin ) chemotherapy . RAD001 take orally daily bevacizumab administer intravenously every 14 day . In addition study treatment , blood sample sample patient tumor previous surgery available collect research .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients may may measurable disease . Measurable disease define accord RECIST criterion . If patient previous radiation marker lesion ( ) , must evidence progression since radiation complete . Minimum four week since major surgery , completion radiation , completion prior systemic anticancer therapy ( adequately recover acute toxicity prior therapy ) Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fast triglyceride ≤ 2.5 x ULN . Performance status £ 2 Signed inform consent . Prior treatment investigational drug within precede 4 week Chronic treatment systemic steroid another immunosuppressive agent Patients receive immunization attenuate live vaccine within one week study entry study period Uncontrolled brain leptomeningeal metastases Other malignancy within past 5 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin . Patients severe and/or uncontrolled medical condition condition could affect participation Uncontrolled diabetes mellitus A known history HIV seropositivity Impairment gastrointestinal function gastrointestinal disease Patients active bleeding diathesis oral antivitamin K medication ( except low dose coumadin ) Women pregnant breast feeding , woman able conceive unwilling practice effective method birth control . Patients receive prior treatment mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) . Patients know hypersensitivity RAD001 ( everolimus ) , rapamycins ( sirolimus , temsirolimus ) excipients , bevacizumab Patients serious nonhealing wound , ulcer , bone fracture . Patients know hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibody</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Recurrent</keyword>
	<keyword>ovarian</keyword>
	<keyword>fallopian tube</keyword>
	<keyword>primary peritoneal</keyword>
	<keyword>cancer</keyword>
	<keyword>Recurrent ovarian , fallopian tube , primary peritoneal cancer</keyword>
</DOC>